This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.
Seattle Genetics will also be eligible for further progress-dependent milestone payments of up to $2.6bn. ... Seattle Genetics will receive $85m in prepaid research and development payments to be applied to Merck’s global development funding obligations
If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... Seattle is seeking approval for tucatinib in combination
Seattle Genetics and partner Astellas have reported positive results from an early clinical trial of their antibody drug conjugate Padcev in combination with Merck &Co/MSD’s Keytruda in first-line ... line setting," said Roger Dansey, chief medical
In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
However, J&J is not alone in the bladder cancer market. Seattle Genetics and Astellas claimed approval in the US for Padcev (enfortumab vedotin) last week, as a later-line therapy
Plans to expand use into earlier bladder cancer treatment. Seattle Genetics and Astellas have claimed approval in the US for Padcev, an antibody-drug conjugate (ADC), as a later-line therapy ... That would drive a sizeable step up in Seattle’s turnover,
More from news
Approximately 12 fully matching, plus 27 partially matching documents found.
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Winding back to last February (DW Issue 80), Immunomedics announced a licensing agreement with
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....